SEC Company Response from Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282) (SYRE) — Feb 11, 2019
Spyre Therapeutics, Inc. (SYRE) (CIK 0001636282)
Date: Feb. 11, 2019 · CIK: 0001636282 · Accession: 0001193125-19-034172
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228967
Letter
Acceleration Request
AEGLEA BIOTHERAPEUTICS, INC.
901 S. MoPac Expressway
Barton Oaks Plaza One, Suite 250
Austin, TX 78746
February 11, 2019
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Attention: Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance
Re: Aeglea BioTherapeutics, Inc.
Registration Statement on Form S-3
Filed December 21, 2018
File No. 333-228967
Via EDGAR - Acceleration Request
Requested Date: February 13, 2019
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Amanda Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
Sincerely,
AEGLEA BIOTHERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request AEGLEA BIOTHERAPEUTICS, INC. 901 S. MoPac Expressway Barton Oaks Plaza One, Suite 250 Austin, TX 78746 February 11, 2019 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Suzanne Hayes Assistant Director Office of Healthcare and Insurance Re: Aeglea BioTherapeutics, Inc. Registration Statement on Form S-3 Filed December 21, 2018 File No. 333-228967 Via EDGAR - Acceleration Request Requested Date: February 13, 2019 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Registrant hereby authorizes Robert A. Freedman or Amanda Rose, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. Sincerely, AEGLEA BIOTHERAPEUTICS, INC. By: /s/ Charles N. York II Charles N. York II Chief Financial Officer cc: Anthony G. Quinn, Chief Executive Officer Aeglea BioTherapeutics, Inc. Robert A. Freedman, Esq. Amanda Rose, Esq. Fenwick & West LLP